Assenagon Asset Management S.A. Has $32.82 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Assenagon Asset Management S.A. raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 1,196.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 336,237 shares of the medical equipment provider's stock after purchasing an additional 310,301 shares during the period. Assenagon Asset Management S.A. owned approximately 0.49% of Lantheus worth $32,817,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of LNTH. Kestra Investment Management LLC bought a new stake in Lantheus in the 4th quarter valued at about $27,000. Summit Securities Group LLC bought a new stake in Lantheus in the 4th quarter valued at about $37,000. Parkside Financial Bank & Trust boosted its holdings in Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares during the period. UMB Bank n.a. boosted its holdings in Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 381 shares during the period. Finally, 1620 Investment Advisors Inc. bought a new stake in Lantheus in the 4th quarter valued at about $125,000. Institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Truist Financial cut their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, B. Riley cut their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $132.67.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director now directly owns 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.50% of the stock is owned by corporate insiders.

Lantheus Stock Performance

Shares of Lantheus stock traded down $0.01 on Monday, reaching $77.82. 809,855 shares of the stock were exchanged, compared to its average volume of 1,012,710. The firm's 50 day moving average is $88.50 and its 200-day moving average is $91.32. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89. The firm has a market cap of $5.38 billion, a PE ratio of 12.95 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.69 earnings per share. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.